Disease Progression: Clinical Trials

2 trials for Disease Progression, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 recruiting. 2 Early Phase 1.

By phase and status

PhaseTrialsStatus
Early Phase 12Active not recruiting 1, Recruiting 1

Follow Disease Progression: new trials by email Literature Review of Disease Progression trials Research Report on Disease Progression

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effects of Ublituximab on Motor Functions in Multiple Sclerosis
Ublituximab - Multiple Sclerosis (MS) - Relapsing-remitting
Early Phase 1RecruitingGeorgia State University252025-11-132026-02-09
Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors
Pembrolizumab - Solid Tumors, Identified by NGS, PCR or IHC
Early Phase 1Active not recruitingMemorial Sloan Kettering Cancer Center172019-02-202026-03-05

Narrower conditions

Multiple Sclerosis, Relapsing-Remitting (1)  ·  Pathologic Complete Response (1)

Broader conditions

Disease Attributes (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Autoimmune Diseases (1)  ·  Autoimmune Diseases of the Nervous System (1)  ·  Demyelinating Autoimmune Diseases, CNS (1)  ·  Demyelinating Diseases (1)  ·  Immune System Diseases (1)  ·  Multiple Sclerosis (1)  ·  Nervous System Diseases (1)

Interventions

pembrolizumab (1)  ·  ublituximab (1)

Sponsors

Georgia State University (1)  ·  Memorial Sloan Kettering Cancer Center (1)

Countries

United States (2)

Top investigators

Yelena Janjigian, MD (1)

Results publications

PMID 33416261, PMID 35179774